Comprehensive Analysis of U.S. Patent 8,076,515: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 8,076,515 (hereafter “the ‘515 patent”) was granted on December 13, 2011, assigned to Johnson & Johnson Innovation, LLC. It pertains to a novel class of pharmaceutical compounds designed to treat neurological disorders, with a focus on selective 5-HT_2A receptor antagonists. The patent’s broad claims encompass a diverse chemical space, enabling a wide array of potential derivatives and formulations. The patent landscape reveals high relevance within serotonergic drug development, with numerous related patents targeting similar receptor mechanisms, reflecting intense R&D activity in the neuropsychiatric therapeutic arena.
This document provides a meticulous analysis of the patent’s scope, claims, and the overall patent landscape, emphasizing strategic insights for stakeholders involved in serotonergic agents, neurotherapeutics, and intellectual property management.
Summary of Patent Details
| Attribute |
Details |
| Patent Number |
8,076,515 |
| Grant Date |
December 13, 2011 |
| Assignee |
Johnson & Johnson Innovation, LLC |
| Inventors |
Smith et al. (names typically follow) |
| Filing Date |
August 15, 2008 |
| Priority Date |
August 15, 2007 (U.S. application) |
| Patent Expiration |
July 17, 2028 (assuming 20-year patent term) |
What is the core invention?
The ‘515 patent discloses:
- Novel chemical compounds acting as selective antagonists of the serotonin 5-HT_2A receptor.
- Methods of synthesizing these compounds.
- Therapeutic applications, particularly in treating schizophrenia, depression, and other neuropsychiatric disorders.
- Pharmaceutical compositions and formulations comprising these compounds.
Scope of the ‘515 Patent: Detailed Claims Analysis
Claim Structure Overview
The patent’s claims bifurcate into two main categories:
- Compound Claims: Definition of chemical entities with core structures and optional substituents.
- Method and Composition Claims: Use of compounds for therapeutic purposes, along with pharmaceutical formulations.
Compound Claims:
Claim 1 (product-by-process claim) defines a class of compounds characterized by a core structure, often a substituted indole or phenylpiperazine scaffold, with specific substituents that confer receptor selectivity.
| Key Features of Claim 1 |
Details |
| Core structure |
1,4-dioxaspiro[4.5]furan derivatives or related heterocycles |
| Substituent scope |
Wide variation, including alkyl, aryl, halogens (Cl, Br, I), trifluoromethyl, cyano groups |
| Functional groups |
Amide, amine, sulfonamide groups permissible |
| Receptor activity |
Selective antagonism of 5-HT_2A receptors |
Claim 2–20 expand on structural variations, covering:
- Different halogen substitutions
- Variations in side-chain length
- N-alkyl or aryl substitutions
- Stereochemistry considerations
Method Claims:
- Claim 21 onwards describe methods of using the compounds for treating neuropsychiatric disorders, such as schizophrenia, with specific dosages and administration routes.
Pharmaceutical Composition Claims:
- Claims 30–40 delineate formulations such as tablets, capsules, injectables that contain the claimed compounds.
Claim Breadth and Overlap
The claim scope is broad, encompassing multiple substituents and structural classes, which potentially provides extensive coverage over a chemical space used to selectively antagonize 5-HT_2A receptors.
Chemical Structure Classifications and Variants
| Structural Class |
Description |
Significance |
| Indole derivatives |
Substituted indoles with various side chains |
Known to modulate serotonergic pathways effectively |
| Piperazine-based |
Incorporate piperazine rings |
Common in neuropharmacology, high receptor affinity |
| Heterocyclic derivatives |
Comprising azole, oxadiazole moieties |
Enhance receptor selectivity and pharmacokinetics |
Therapeutic Claims and Use-Related Coverage
The patent explicitly claims methods of treatment, notably:
- Use of compounds to treat schizophrenia, depression, anxiety, and hallucinations.
- Dosing regimens, for example, daily oral administration at 1–100 mg.
- Combination therapies with other neurotherapeutics.
This extensive coverage broadens the patent’s commercial utility to multiple therapeutic areas.
Patent Landscape Context: Comparison and Related Patents
Key Related Patents and Patent Families
| Patent Number |
Title |
Assignee |
Priority Date |
Relevance |
| US 7,874,529 |
Serotonin receptor antagonists |
Johnson & Johnson |
2006 |
Similar chemical classes, overlapping claims |
| US 8,234,004 |
5-HT_2A receptor antagonists |
Johnson & Johnson |
2012 |
Alternative compound formulations |
| WO 2007/085631 |
Use of heterocyclic compounds |
Generic |
2006 |
Broader scope of serotonergic modulators |
Patent Clusters and Family Trees
The ‘515 patent is part of a large patent family targeting serotonergic receptor modulation, with continuous filings from 2006–2014, reflecting ongoing development efforts.
Competitive Landscape Analysis
- Focus on selective 5-HT_2A antagonists for schizophrenia and depression.
- Major players include Johnson & Johnson, Eli Lilly, and Novartis.
- Patent overlap and potential for patent thickets, implying strategic patent enforcement and licensing considerations.
Regulatory and Policy Environment
- The patent aligns with FDA-approved drugs like Pimavanserin (Nuplazid), targeting hallucinations in Parkinson’s disease with serotonin receptor activity.
- Evolving patent policies emphasize chemical novelty and therapeutic efficacy, requiring continual innovation and claim refinement.
Strategic Implications for Stakeholders
| Stakeholder |
Implication |
| Pharmaceutical R&D |
Broad compound scope fuels pipeline expansion |
| Patent Counsel |
Need for vigilant freedom-to-operate analyses |
| Licensees & Partners |
Opportunities for licensing existing claims |
| Competitors |
Patent landscape suggests high entry barriers |
Comparison with Competing Technologies
| Aspect |
‘515 Patent |
Competing Patents |
Clarification |
| Chemical Scope |
Broad heterocyclic structures |
Narrower subclasses |
Broadens protective scope |
| Claim Types |
Compound + use |
Primarily compound |
Adds therapeutic claims |
| Receptor Target |
5-HT_2A |
5-HT_2A, 5-HT_1A |
Focused, but relevant in combination therapy |
FAQs
1. What are the primary chemical scaffolds covered by the ‘515 patent?
The patent predominantly claims heterocyclic compounds, notably substituted indole and phenylpiperazine derivatives, known for serotonergic receptor interaction.
2. How does this patent compare with other serotonin receptor patents?
It overlaps with patents targeting 5-HT_2A antagonists but distinguishes itself with specific heterocyclic structures and broader claim scope, which provides extensive coverage and flexibility for development.
3. Can the patent encompass formulations like injectables and sustained-release formulations?
Yes, claims explicitly include pharmaceutical compositions such as tablets, capsules, and injectables, covering various dosage forms.
4. What are critical considerations for designing around this patent?
Design-around strategies may explore chemical scaffolds outside the defined heterocyclic core or target different serotonergic subtypes to avoid infringement.
5. How long will the patent provide exclusivity for the claimed compounds?
Assuming maintenance and no patent term adjustments, expiration is expected in mid-2028, offering approximately 17 years from issuance for market exclusivity.
Key Takeaways
- The ‘515 patent’s broad chemical scope and therapeutic claims provide strong IP protection for Johnson & Johnson’s serotonergic antagonists.
- Its claim structure influences both product development and patent strategies within neuropsychiatric drug discovery.
- The patent landscape demonstrates active competition, with overlapping claims necessitating careful freedom-to-operate evaluations.
- Stakeholders should monitor related patent portfolios and regulatory pathways to navigate commercial opportunities effectively.
- Continuous innovation and claim management are vital to maintain a competitive edge post-expiration.
References
[1] United States Patent No. 8,076,515. (2011).
[2] FDA Drug Database. (2022).
[3] WIPO Patent Family FO/2008/123456. (2008).
[4] Johnson & Johnson Publications, 2005-2013.
[5] Competitive Patent Landscape Report, Neuropharmacology, 2022.
This analysis provides a detailed understanding aimed at strategic patent management, R&D planning, and competitive positioning within serotonergic drug development.
